

Interview Summary	Application No.	Applicant(s)	
	09/724,961	SCHENK, DALE B.	
	Examiner	Art Unit	
	Christopher Nichols, Ph.D.	1647	

All participants (applicant, applicant's representative, PTO personnel):

(1) Examiner Christopher Nichols, Ph.D.

(3) Rosemarie Celli.

(2) SPE Gary Kunz, Ph.D.

(4) Joe Liebeschuetz.

Date of Interview: 06 October 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: 1,5,7-12,14,15,19-23,26 and 31-40.


Identification of prior art discussed: Walker et al. (July 1994) "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody." Journal of Neuropathology and Experimental Neurology 53(4): 377-383.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: (a) 35 U.S.C. 112 1st rejection, (b) Preamble amendment "prophylactically or therapeutically", (c) Alzheimer's disease versus amyloidogenic in terms of scope of enablement, (d) human IgG1 not equivalent to mouse IgG1, (e) human IgG1 stimulates phagocytosis, important for therapy, (f) active versus passive immunization therapy (Abeta peptides versus anti-Abeta antibodies).

**No Applicant Summary deemed necessary.*

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required